Neuroleptic-induced Parkinsonism: Clinicopathological study. - Wikidata - awgldk - TriplyDB

Neuroleptic-induced Parkinsonism: Clinicopathological study.

Neuroleptic-induced Parkinsonism: Clinicopathological study.

http://www.wikidata.org/entity/Q37340484

about

Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.Insights into Pathophysiology from Medication-induced Tremor.Movement disorders and chronic psychosis: Five new things.Microstructural white matter alterations in patients with drug induced parkinsonism.Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

P2860

Q28550219-13581EEE-1C0E-4BDF-8C42-29F0A9B8AF38 Q37653322-BFF170ED-271B-4EE2-9F13-22D2857CD4C1 Q47128750-E4F05DA7-0848-4689-82DB-F4460DDE264E Q47398683-20CE4F62-B200-4E1B-B59B-58BD3EE971D2 Q47681149-3DFB3DD1-F1B6-42DC-B4A2-0416300925D6 Q47838959-0508D071-DD8D-4174-A6C2-E7BAFDFD2D89 Q50014594-890B1528-0184-47D9-9E5D-353EB5AA7D66

P2860

Neuroleptic-induced Parkinsonism: Clinicopathological study.

http://www.wikidata.org/entity/Q37340484

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@en

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@nl

type

label

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@en

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@nl

prefLabel

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@en

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@nl

P1433

Q37340484-DFC5A484-4036-4641-8729-D350F1C6CF9A

P1476

Q37340484-BEB7CAAC-2720-42B9-B4FA-019596953DDC

P2093

Q37340484-24B7CB34-72A4-4A5A-B9B5-60518E00767A

Q37340484-431E0C8E-0B54-4342-A3AC-940C130EEC17

Q37340484-904C4C1D-FE9B-4E27-A680-16B815086409

Q37340484-97DCC002-ABF6-49F6-AD41-8C95862A4B46

P2860

Q37340484-00193AC8-E604-45BD-97E0-1A325226509D

Q37340484-0E72B316-6F7D-41E4-99D8-0A41E29F02DB

Q37340484-3257B697-D8E1-4099-9587-3F368D772A9B

Q37340484-576AA16E-EACC-4768-987D-3B6E7F76A7C0

Q37340484-5B1D0AAE-1735-45C2-9D15-7D4BEB30498E

Q37340484-653B552A-1E39-4CE1-ADCE-82E5B40FC298

Q37340484-71279991-267B-44AF-B340-A6540DCDE858

Q37340484-96F13906-0579-4B39-8146-F24E6FD3B73F

Q37340484-9D77FF62-97B3-446A-BDC4-681A1DD9EE9B

Q37340484-A4D0DE99-0B58-4BA4-B4C0-4883CE48E246

P304

Q37340484-10C3E9C0-D2F4-461E-B2F6-608F40A046E5

P31

Q37340484-1B5ED575-43DA-4194-8607-F3D2BF835F3E

P356

Q37340484-A7049AC3-6D8F-4B6E-A57B-E6E42CB7D523

P407

Q37340484-3034FAA9-0145-4730-B866-46C996BFD277

P433

Q37340484-BCBA2560-888E-43C0-BAF3-3F59E3FE71DE

P478

Q37340484-A34B610A-1567-4732-B0CE-42F23EEE4C63

P577

Q37340484-BAF663D2-F421-4725-9119-99DC0B5B7F5B

P5875

Q37340484-D8189A16-6EFA-48D3-8EEB-A297463653EF

P698

Q37340484-277AA5C5-3AB8-46D9-B56F-5533E2861B87

P921

Q37340484-3DE54DB8-1D61-47F9-9950-1BB7D912CE65

P932

Q37340484-ABE4F7E6-E3C9-4C1E-A72A-1ED41561858F

P356

P1433

Movement Disorders

P1476

Neuroleptic-induced Parkinsonism: Clinicopathological study.

@en

P2093

Alex Rajput

http://www.w3.org/2001/XMLSchema#string

Ali H Rajput

http://www.w3.org/2001/XMLSchema#string

Christopher A Robinson

http://www.w3.org/2001/XMLSchema#string

Umar A Shuaib

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinsonism: onset, progression and mortality

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

Ageing and Parkinson's disease: substantia nigra regional selectivity

The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Diagnostic criteria for Parkinson disease.

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations.

Parkinsonism following neuroleptic exposure: A double-hit hypothesis?

P304

360-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26467

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286994255

http://www.w3.org/2001/XMLSchema#string

P698

26660063

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5064745

http://www.w3.org/2001/XMLSchema#string